Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2007 xxxx generálním xxxxxxxxx XXXXXX, xxxxxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾, xxxxxxxx xxxxxxxxx nového xxxxx Přílohy I - Xxxxxxx zakázaných xxxxx x xxxxx dopingu.

Xxxxxxx X vstoupila x xxxxxxxx v xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2008 x xxxxx xxxx xxxxxxxxx x xxxxxxxx i xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx Příloha I Xxxxxxxxxxx xxxxxx proti xxxxxxx xx sportu xx znění xxx xxx 2007, vyhlášená xxx x. 59/2007 Xx. m. x.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx do xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

x. Xxxxxxxx * XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); xxxxxxxxxxxxxx; formebolon; xxxxxxxxx (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-hydroxytestosteron (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; methandriol; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); methyl-1-testosteron (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxx; nandrolon; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); norboleton; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; oxymetolon; xxxxxxxxxxx ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); quinbolon; xxxxxxxxxx; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

b. Xxxxxxxxx ** XXX:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), testosteron x xxxxxxxxxxx xxxxxxxxxx x isomery:

5α-androstan-3α,17α-diol androst-5-en-3β,17α-diol

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-androstan-3β,17β-diol epi-dihydrotestosteron

xxxxxxx-4-xx-3α,17α-xxxx 3α-xxxxxxx-5αxxxxxxxxx-17-xx

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

androst-5-en-3β,17α-diol 19-norandrosteron

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

xxxxxxx-5-xx-3α,17β-xxxx

X xxxxxxxxx, kdy xxxx xxxx produkovat xxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx, xxxx xx xxx xx to, xx Xxxxxx xxxxxxxx xxxx Xxxxxxxxx látku a xxxx hlášen pozitivní Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxx se koncentrace Xxxxxxxx xxxxx nebo xxxxxx metabolitů nebo xxxxxxxxxxx a/nebo xxxx xx jakýkoli jiný xxxxxxxxx poměr xx Xxxxxx Sportovce xxxxxxxx xxxxxxxxx od rozmezí xxxxxx, xxxxx se xxxxxxxx vyskytují x xxxx xxx, že xxxxxxxxxx xxxxxxxx endogenní xxxxxxxx. Xxxxxx se xxx xx to, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx x xxxxxxx xxxxxxx, xxxxx Xxxxxxxxx xxxxxxx, xx xx xxxxxxxxxxx Zakázané xxxxx xxxx xxxxxx xxxxxxxxxx xxxx indikátorů x/xxxx příslušný xxxxx xx Vzorku Sportovce xxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxxxxx xxxxxx.

Xxxx xx xxx za xx, xx Vzorek Xxxxxxxxx obsahuje Zakázanou xxxxx a xxxxxxxxx xxxxxxx Pozitivní xxxxxxxxxxx xxxxx xx všech xxxxxxxxx x při xxxxxxxxx xxxxxxxxxxx, xxxxx xxx xxxxx spolehlivé xxxxxxxxxx metody (např. XXXX) xxxxxxxx, xx xx Zakázaná látka xxxxxxxxxx xxxxxx. X xxxxxxx případě xxxx xxxxx provádět xxxxx xxxxxxx.

Xxxx xx xxxxxxx xxxxxxxx analýzy xxxxxxxx xxxxxxxxxxx od xxxxxxx xxxxxx, xxxxx xx xxxxxxxx vyskytují x xxxx a xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx původ Xxxxxxxx xxxxx, xxx xxxxxxxx xxxxxx použití Xxxxxxxx látky, xxxx xxxx. xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxxxx steroidními xxxxxxx, xxxx xxxx xxxxxxxxx xxxxxxxxx poměr X/X xxxxx xxx xxxxx (4) xx xxxxx (1) x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx xxxxx, xxxxxxx xxxxxxxxx Xxxxxxxxxxxxx xxxxxxxxxx další xxxxxxx porovnáním xxxxxxxx xxxxxxxxxx xxxxx nebo xxxxxxxxxx xxxxxxxxxx xxxxx.

Xx-xx vyžadováno takové xxxxx xxxxxxx, pak xxxxxxxx bude xxxxxxxxxx xxxxxx xxxx neobvyklý x xx xxxx xxxxxxxxx. Pokud xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxxxx provádět xxxxx šetření, x xxxx xx xxx xx xx, xx Xxxxxx xxxxxxxx Zakázanou xxxxx. Pokud nebyla xxxxxxx xxxxxxxxxx analytická xxxxxx (xxxx. XXXX) x xxxxxx x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, bude xxxxxxx xxxxxxxxxxxxxx profil Xxxxxxxxx xxx, xx xxxx xxxxxxxxxx Xxxxxxxxxxxxxx xxxxxxxxxx x xxxxxxxxxxxxx 3 xxxxxxxx xxxxxxx xxxxxxxx xxx xxxxxxxxxxx xxxxxxxx. Xxxxxxxx, xxxxx xxxxxxxxxx tuto xxxxxxxxxxxxxx xxxxxx, xxxx hlášen xxxx xxxxxxxxx. Xxxxx xxxxxxxxxxxxxx xxxxxx Xxxxxxxxx, xxxxxxxx xxxxxxxxxx testy, xxxx fyziologicky xxxxxxxx, xxxx se xxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález.

V xxxxxxxx xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx může být x xxxx xxxxxx xxxxxxx xxxxxxxx endogenního xxxxxx ve velice xxxxxx xxxxxxxxxxxxx (xx/xx). Xxxxx laboratoř xxxxxx xxxxx nahlásila a xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (např. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx látky, xxxx xxx xxxxxxxxx další xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx (xxxxxxxxxx testů).

Xxxxx xxxxxxxxx xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx 19-xxxxxxxxxxxxxxx, bude se xx xxxxxxxxx za xxxxxxx x přesvědčivý xxxxx xxxxxxxxxx xxxxxx Xxxxxxxx xxxxx. X xxxxxxx xxxxxxx není xxxxx xxxxxxxx xxxxx xxxxxxx.

X xxxxxxx, xx Xxxxxxxxx nebude xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxxx, bude xx xxx za to, xx Xxxxxx Xxxxxxxxx xxxxxxxx Zakázanou xxxxx.

2. Ostatní xxxxxxxxxx xxxxx, zahrnující:

Klenbuterol, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), tibolon, xxxxxxx, xxxxxxxxxx, xxx xx x omezením xxxxx na ně.

X2. XXXXXXX X XXXXXXXX XXXXX

Následující xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Erytropoetin (XXX);

2. Xxxxxxx xxxxxx (xXX), xxxxxxxx podobné xxxxxxx faktory (xxxx. XXX-1), xxxxxxxxxx růstové xxxxxxx (MGF);

3. Xxxxxxxxxxxxx (xxxx. LH, xXX), xxxxxxxx jen x mužů;

4. Xxxxxxxx;

5. Xxxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Pokud Xxxxxxxxx xxxxxx xxxxxxxx, xx koncentrace byla xxxxxxxxx xxxxxxxxxxxxx xx xxxxxxxxxxxx xxxxxx, xxxx xx mít xx xx, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx (xxx xx xxxxxxx xxxx) x xxxxxxxxx, xxx xxxxxxxxxxx Zakázané xxxxx xxxx xxxxxx xxxxxxxxxx či indikátorů x/xxxx xxxxxxxxx xxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxx xxxxxxxx hodnoty xxxxxxxx xxxxxxxx x xxxx tak, xx xxxxxxxxxxxx normální xxxxxxxxx xxxxxxxx.

Pokud xxxxxxxxx xxxxxxxxx, xx užití xxxxxxxxxx xxxxxxxxxx xxxxxx, xx Xxxxxxxx xxxxx xx exogenního xxxxxx, xxxx xx mít xx to, xx Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxx xxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx.

S3. XXXX-2 AGONISTÉ

Všichni xxxx-2 xxxxxxxx xxxxxx xxxxxx D- x X-xxxxxxx xxxx xxxxxxxx.

Xxxxxxxx xxxx xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, xxx xxxxx xx při xxxxxxxx xxxxx udělení zkrácené xxxxxxxxxxxx xxxxxxx.

X xxxx xxxx xxxxxxx xxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxx, xxxx xxxxx xxxxxxxxxxx (xxxxx plus xxxxxxxxxx) xxxxx xxx 1000 nanogramů x 1 xxxxxxxxx xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx neprokáže, že xxxxxxxxxx výsledek xxx xxxxxxxx xxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxxx.

X4. XXXXXXXXXXX X XXXXXXXXXX XXXXXXX

Xxxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SERM), xxxxxxxx:

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX LÁTKY

Xxxxxxxxx xxxxx xxxx xxxxxxxx. Xxxxxxxx:

Xxxxxxxxx*, epitestosteron, probenecid, xxxxxxxxxx alfa-reduktázy (např. xxxxxxxxxx, xxxxxxxxxx), xxxxxxxxxxxxxxx (xxxx. albumin, xxxxxxx, xxxxxxxxxxxxxxxxx) a xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx účinky.

Diuretika xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, furosemid, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx xxxx xxxxxx, xxxxx xxx Xxxxxxxxx xxxxxxxx diuretika ve xxxxxxx s xxxxxxxx xxxx xxxxxxxxxxx hladinou xxxx Xxxxxxxx xxxxx (xxxxx).

X1. XXXXXXXXX XXXXXXX XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

M2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

X3. XXXXXX XXXXXX

Xxxxxxxxxxxxxx xxxxxxx xxxxx, genů, xxxxxxxx elementů, xxxx xxxxxxxxxx exprese genů, xxxxx mají schopnost xxxxxx xxxxxxxxx výkon, xx xxxxxxxx.

X6. XXXXXXXXXXX

Všechna xxxxxxxxxxx (xxxxxx xxxx xxxxxx případných xxxxxxxxx (X- x X-) xxxxxxx) jsou zakázaná, x výjimkou xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxx x xxxxxxxxxxx xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx rok 2008.

Xxxxxxxxxxx xxxxxxxx:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, efedrin****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenetylin, xxxxxxxxxxx, fenkamfamin, fenkamin, xxxxxxxxxxx, fenprometamin, fenproporex, xxxxxxxxx, 4-fenylpiracetam (xxxxxxxx), xxxxxxxxxx, heptaminol, xxxxxxxxxxxx, xxxxx***, xxxxxxxxxxx, kokain, xxxxxxxxxxx, xxxxxxxxxx, levmetamfetamin, xxxxxxxxx, xxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx (X-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, methylendioxymetamfetamin, xxxxxxxxxxxxx, xxxxxxxx, modafinil, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, pentetrazol, p-methylamfetamin, xxxxxxxxx, xxxxxxxxxxxxxx, selegilin, xxxxxxxxxx, strychnin, tuaminoheptan x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

Xxxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxx xxxxxxxx x xxxxx xxxxxx xxxx xxxxxxxxxx xx specifickou xxxxx pouze, xxxxx Xxxxxxxxx xxxxxxx, xx xxxx xxxxxxxxx xxxxxxxxxx x xxxxxxx léčebných xxxxxxxxxxx umožňuje xxxxxxxxx xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxx je x xxx menší pravděpodobnost, xx bude xxxxxxx xxxxxxxx xxxx xxxxxxxxx xxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Buprenorfin, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.

S8. XXXXXXXXXXX

Xxxxxxxxxxx (např. xxxxx, xxxxxxxxx) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx xxxx xxxxxxxx. Xxxxxx xxxxx xxxxxxxx xxxxxxxxxxxxx xxxxxxx.

Xxxx xxxxxxx xxxxxxxx xxxxxxxx (xxxxxxxxxxxx, do xxxxx xxxxxx, xx xxxxx xxxxxx, epidurální, xx xxxx) x xxxxxxxxx xxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxx x xxxxxxxx níže xxxxxxxxx.

Xxxxxxx xxxxxxxxx xxxxxxxx xx potíže xxxxx (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), xxxx, xxxxx, oční, xxxxxx xxxxx xxxxxxx xxxxxx, xxxxxxxx xxx x xxxxx xxxxxx xxxxxxxx x xxxxxxxxxx xxxxxx xxxxx terapeutické výjimky.

P1. XXXXXXX

Alkohol (xxxxxx) xx zakázaný pouze Xxx soutěži x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx provádět xxxxxxxx zkouškou a/nebo xxxxxxxx krve. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx pravidla (xxxxxxxxxxxxx xxxxxxx) je xxx xxxxxx xxxxxxxx uvedena x xxxxxxxxx.

∙ Xxxxxxxxxxxx sport (XXX) (0.10 g/l)

∙ Xxxxxx (WKF) (0.10 x/x)

∙ Xxxxxxx xxxxxx a parašutismus (XXX) (0.20 g/l)

∙ Xxxxxxxxxxx (FITA, XXX) (0.10 x/x)

∙ Moderní pětiboj (XXXX) xxx xxx xxxxxxxxxx xx xxxxxxxx (0.10 g/l)

∙ Xxxxxxxxxxx sport (XXX) (0.10 x/x)

∙ Xxxxx motorismus (XXX) (0.30 x/x)

∙ Kuželky (XXX) (0.10 x/x)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx jinak určeno, xxxx-xxxxxxxxx jsou zakázány xxxxx Xxx soutěži x xxxxxxxxxxxxx sportech.

∙ Xxxxxxxxxxxx sport (XXX)

∙ Xxxxxxxx (XXXX)

∙ Xxxx (XXXX)

∙ Xxxxx (XXX)

∙ Xxxxxxx (XXX)

∙ Gymnastika (XXX)

∙ Xxxxxxxx (XXXX) - "xxxxx xxxx" - jen xxxxxxxxxxx

∙ Xxxxxxx (XXX)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Mimo xxxxxx)

∙ Lyžování (XXX) - xxxxx na xxxxxx x akrobatické xxxxxxxx-xxxxx a X-xxxxx, x snowboard X-xxxxx x "big xxx"

∙ Xxxxxxx xxxxxxx (XXXX) - xxx xxxxxxxxxx xx střelbou

∙ Xxxxxxxxxxx xxxxx (XXX)

∙ Xxxxxxxx x xxxxxxx xxxxxx (XXXX, XXX "xxxxx")

∙ Xxxxxxx (ISSF, XXX) (xxxxxxxx také Xxxx xxxxxx)

∙ Xxxxx xxxxxxxxxx (UIM)

∙ Zápas (XXXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, celiprolol, esmolol, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx

"Xxxxxxxxxx xxxxx"* xxxx xxxxxxxxxxx xxxx:

∙ Xxxxxxx Beta-2 xxxxxxxx x xxxxxxxx, xxxxx xxxxxxxxxxx (volného xxxx xxxxxxxxxxx) při xxxxxxxx větším xxx 1000 xx/xx moči x xxxxxxxxxxxx (xxxxxxx xx skupině X 1.2 Xxxxxxx xxxxxxxxxx xxxxx);

∙ Inhibitory xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxx, famprofazon, xxxxxxxxxxxxx, haptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, ortetamin, xxxxxxxxx, xxxxxxxxxxxxxx, selegilin, xxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxx xxxxxxx xxxxxxxxxxx neuvedená xxxxxxxx v xxxxxx X6, xxx která Xxxxxxxxx xxxxxxx, xx xxxxxxx podmínky xxxxxxx x xxxxxx X6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Glukokortikosteroidy;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"X Seznamu xxxxx být xxxxxxxxxxx xxxxxxxxxx látky, které xxxxxxxx xxxxxxxx neúmyslné xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxxxx xxxxxxxx x běžných xxxxxxxxx xxxxxxxxxxx, xxxx x nichž je xxxxx pravděpodobnost, xx xxxxx xxxxxxx xxxxxxxx xxxx xxxxxxxxx činidla." Xxxxxxxx xxxxxxxxxxxxxxx pravidla xxxxxxxxxx xxxxxxxx xxxxx xxxx znamenat snížený xxxxxx xx xxxxxxxxxxx, xx "...Xxxxxxxxx může xxxxx xxxxxxxx, že Xxxxxxx specifické xxxxx xxxxxx xxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx...".

Xxxxxx předpis x. 2/2008 Xx. m. x. xxxxx xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx x. 2/2008 Xx. x. x. xxx xxxxxx xxxxxxx předpisem č. 8/2009 Sb. m. s. x xxxxxxxxx od 7.2.2009.

Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x odkazech není xxxxxxxxxxxxx, pokud se xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.